AnaSpec Introduces New ClearPointTM beta-Amyloid Peptides
ClearPointTM peptides are AnaSpec’s trademark collection of heavy or stable isotope labeled peptides and amino acids.
San Jose, CA, January 11, 2009 --(PR.com)-- AnaSpec has announced the release of its newest collection of ClearPointTM b-Amyloid peptides.
ClearPointTM peptides are AnaSpec’s trademark collection of heavy or stable isotope labeled peptides and amino acids. These peptides can be used for the quantitative analyses of b-Amyloid peptides in biological fluids using mass spectrometry (MS). The inclusion of internal heavy isotope labeled peptide standards makes mass spectrometry an absolute quantitation (AQUA) method for the peptide of interest.2
b-Amyloid (1-40) and (1-42) peptides have been used as biomarkers of Alzheimer's disease (AD). Historically, ELISA assays have been used in the quantitation of these peptides. However, technical challenges such as the tendency of b-Amyloid (1-40) and (1-42) peptides to self-aggregate, undergo post-translational modifications or bind to other proteins result in inaccuracies in quantitation when using ELISA.1 Oe, et al. reported the use of [15N]-labeled b-Amyloid peptides as internal standards using immunoaffinity purified CSF.1
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.
For more information visit www.anaspec.com
References
1. Oe, T. et al. Rapid Comm. Mass Spec. 20, 3723 (2006).
2. Harding, S. (ed.) 2007. Biotechnology & Genetic Engineering Reviews. Nottingham Univ. Press, Nottingham.
###
ClearPointTM peptides are AnaSpec’s trademark collection of heavy or stable isotope labeled peptides and amino acids. These peptides can be used for the quantitative analyses of b-Amyloid peptides in biological fluids using mass spectrometry (MS). The inclusion of internal heavy isotope labeled peptide standards makes mass spectrometry an absolute quantitation (AQUA) method for the peptide of interest.2
b-Amyloid (1-40) and (1-42) peptides have been used as biomarkers of Alzheimer's disease (AD). Historically, ELISA assays have been used in the quantitation of these peptides. However, technical challenges such as the tendency of b-Amyloid (1-40) and (1-42) peptides to self-aggregate, undergo post-translational modifications or bind to other proteins result in inaccuracies in quantitation when using ELISA.1 Oe, et al. reported the use of [15N]-labeled b-Amyloid peptides as internal standards using immunoaffinity purified CSF.1
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.
For more information visit www.anaspec.com
References
1. Oe, T. et al. Rapid Comm. Mass Spec. 20, 3723 (2006).
2. Harding, S. (ed.) 2007. Biotechnology & Genetic Engineering Reviews. Nottingham Univ. Press, Nottingham.
###
Contact
AnaSpec, Inc.
Ping Yang
408-452-5055
www.anaspec.com
Ping Yang
408-452-5055
www.anaspec.com
Contact
Categories